RxDoctor Payments Data

Gary Kay, MD

Hematology & Oncology · Elk Grove Village, ILNPI 1205897923

Payments from drug & device makers

$314,085in general payments, 2019–2025

Across 730 payments — averaging $430.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$135K
  • Seagen Inc.$38K
  • Gilead$33K
  • Amgen$24K
  • Coherus Oncology, Inc.$15K
  • Heron Therapeutics, Inc.$15K
  • plus $54K from 54 others

What the payments were for

  • Consulting fees$49,64916%
  • Speaking & faculty fees$225,21972%
  • Travel & lodging$25,4358%
  • Food & beverage$13,5184%
  • Education$2650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC199$134,783
Seagen Inc.45$38,086
Gilead(2 entities)44$33,132
Amgen38$24,239
Coherus Oncology, Inc.22$15,238
Heron Therapeutics, Inc.18$14,505
Pfizer21$9,963
Novartis52$9,657
Dova Pharmaceuticals7$8,493
E.r. Squibb & Sons, L.L.C.12$2,103
Johnson & Johnson(2 entities)15$2,000
GSK5$1,900
AstraZeneca21$1,877
ASD Specialty Healthcare, LLC15$1,691
Pharmaessentia USA Corporation5$1,616
Jazz Pharmaceuticals Inc.5$1,607
Regeneron Healthcare Solutions, Inc.5$1,582
Immunomedics, Inc.1$1,400
Athenex Pharmaceutical Division, LLC1$1,250
Sobi, Inc1$1,150
Taiho Oncology, Inc.1$1,088
Avyxa Pharma, LLC1$1,000
Genentech USA, Inc.45$910
Beigene USA, Inc.5$629
Morphosys, US Inc.3$533
Merck17$372
Puma Biotechnology, Inc.6$336
G1 Therapeutics, Inc.10$267
Pharmacosmos Therapeutics Inc.3$228
AbbVie9$212
Sanofi8$162
Takeda Pharmaceuticals U.S.A., Inc.7$160
Astellas Pharma US Inc7$155
Incyte Corporation9$149
Bristol Myers Squibb5$146
Daiichi Sankyo Inc.6$124
Karyopharm Therapeutics Inc.4$100
Amneal Pharmaceuticals LLC1$89
Mirati Therapeutics, Inc.3$88
Deciphera Pharmaceuticals Inc.3$75
Elekta, Inc.1$70
Eagle Pharmaceuticals, Inc.1$66
Zydus Pharmaceuticals (USA) Inc.1$66
Eisai Inc.3$63
EMD Serono, Inc.3$62
Tesaro, Inc.2$58
Tempus AI, Inc2$50
Stemline Therapeutics Inc.2$48
ADC Therapeutics America, Inc.2$42
Agios Pharmaceuticals, Inc.2$40
Array Biopharma Inc2$38
Pharmacyclics LLC, An Abbvie Company2$35
Dendreon Pharmaceuticals LLC1$35
Bayer2$30
Blueprint Medicines Corporation1$25
Acrotech Biopharma Inc.2$24
Exelixis Inc.1$24
Clovis Oncology, Inc.2$20
AVEO Pharmaceuticals, Inc.1$19
Sun Pharmaceutical Industries Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$314,085 in reported general payments places this provider in the 80th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$703,919
Medicare patients
244
Services billed
36,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide26$598,687
Lenalidomide22$343,481
ImbruvicaIbrutinib12$173,062
EliquisApixaban53$46,458
Letrozole91$2,068
Anastrozole27$462
Tamoxifen Citrate13$432
Dexamethasone29$400
Gabapentin35$354
Pantoprazole Sodium11$212
Warfarin Sodium28$197
Prochlorperazine Maleate17$108
ClopidogrelClopidogrel Bisulfate11$0

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$146$598,68726 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$35$173,06212 claims
PfizerEliquis$9,963$46,45853 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Elk Grove Village

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →